The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2024 | B-cell receptor signaling proteins as biomarkers of progression in CLL
Paul Hengeveld, MD, PhD, Erasmus University, Rotterdam, Netherlands, discusses a study using proteomics to investigate B-cell receptor signaling proteins as biomarkers of progression in patients with chronic lymphocytic leukemia (CLL). The study found that a higher expression of the protein themis2 was associated with a shorter time-to-first-treatment (TTFT). This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
